New Delhi: Centre through an affidavit on Friday informed the Delhi High Court that on May 12, 2021, the Drug Controller General of India (DCGI) has permitted Bharat Biotech to conduct clinical trials on healthy volunteers between 2 years to 18 years of age for its vaccine Covaxin.
The Centre submitted affidavits saying, "The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above, therefore, COVID vaccines are not recommended for persons/children less than 18 years of age. This is also because the clinical trial group during phase 1, phase 2 and phase 3 did not cover the children below 18 years of age."
Read:|Plea in HC to stay Covaxin trial on children
The affidavit has been filed in Delhi HC in response to a petition seeking direction to vaccinate all students of class 12 appearing for board exams.
The Delhi High Court had sought response from the Union of India and the Government of NCT of Delhi on a PIL seeking direction to provide and administer COVID-19 Vaccination free of cost to the students of class 'XII' in Delhi, who will be appearing for their board exams in an off-line mode.
The hearing in the matter was scheduled to be held on Friday but got adjourned for July 16, as the concerned bench didn't assemble.